The prevention and treatment of osteoporosis: A review CME

MedGenMed Medscape General Medicine

Volumn 7, Issue 2, 2005, Pages

  Cosman, Felicia ^a,b  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b HELEN HAYES HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; ANTICONVULSIVE AGENT; ARZOXIFENE; BASODOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; GLUCOCORTICOID; GONADORELIN; GONADORELIN ANTAGONIST; IBANDRONIC ACID; LASOFOXIFENE; MEDROXYPROGESTERONE ACETATE; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN CITRATE; THYROID HORMONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D; VITAMIN K GROUP; ZOLEDRONIC ACID;

ADULT; AGE; AGED; ALCOHOLISM; BODY WEIGHT; BONE DENSITY; BONE MASS; BONE REMODELING; BONE STRENGTH; BONE STRUCTURE; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIZZINESS; DRUG APPROVAL; DRUG MECHANISM; ENDOMETRIOSIS; ENVIRONMENTAL FACTOR; ESOPHAGITIS; ESOPHAGUS STRICTURE; ESOPHAGUS ULCER; FAMILY HISTORY; FEMALE; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GENETIC PREDISPOSITION; HEART INFARCTION; HIP FRACTURE; HOT FLUSH; HUMAN; LEG CRAMP; MALE; MENOPAUSE; NONHUMAN; NUTRITION; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PHYSICAL ACTIVITY; REVIEW; RISK FACTOR; SMOKING CESSATION; STROKE; TREATMENT INDICATION; UNITED STATES; UTERUS CANCER; UTERUS DISEASE; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE; CLINICAL PRACTICE; FRACTURE; PRACTICE GUIDELINE;

FRACTURES, BONE; HUMANS; OSTEOPOROSIS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES;

EID: 25144474941     PISSN: None     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (209)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785-795.
2. Melton LJ. Epidemiology of fractures. In: Riggs BL, Melton LJ, eds. Osteoporosis Etiology, Diagnosis and Management. 2nd ed. Philadelphia, Pa: Lippincott-Raven; 1995:225-248.
3. Seeley DG, Browner WS, Nevitt MC, et al. Which fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures Research Group. Ann Intern Med. 1991;115:837-842.
4. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1995;332:767-773.
5. Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med. 1991;114:919-923.
6. Black DM, Arden NK, Palermo L, et al. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res. 1999;14:821-828.
7. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA. 2001;285:320-323.
8. Melton LJ III, Thamer M, Ray NF, et al. Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12:16-23.
9. Melton LJ III. How many women have osteoporosis now? J Bone Miner Res. 1995;10:175-177.
10. Ray NF, Chan JK, Thamer M, Melton LJ III. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12:24-35.
11. Cooper C, Atkinson EJ, O'Fallon WM, Melton LJ III. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res. 1992;7:221-227.
12. Nevitt MC, Cummings SR. Type of fall and risk of hip and wrist fractures: the study of osteoporotic fractures. The Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc. 1993;41:1226-1234.
13. Browner WS, Pressman AR, Nevitt MC, Cummings SR. Mortality following fractures in older women. The study of osteoporotic fractures. Arch Intern Med. 1996;156:1521-1525.
14. Nevitt MC, Ettinger B, Black DM, et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med. 1998;128:793-800.
15. Kado DM, Browner WS, Palermo L, et al. Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med. 1999;159:1215-1220.
16. Gold DT. The nonskeletal consequences of osteoporotic fractures. Psychologic and social outcomes. Rheum Dis Clin North Am. 2001;27:255-262.
17. Looker AC, Orwoll ES, Johnston CC Jr, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res. 1997;12:1761-1768.
18. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet. 1993;341:72-75.
19. Gilsanz V, Roe TF, Mora S, et al. Changes in vertebral bone density in black girls and white girls during childhood and puberty. N Engl J Med. 1991;325:1597-1600.
20. Liel Y, Edwards J, Shary J, et al. The effects of race and body habitus on mineral density of the radius, hip, and spine in premenopausal women. J Clin Endocrinol Metab. 1988;66:1247-1250.
21. Luckey MM, Meier DE, Mandeli JP, et al. Radial and vertebral bone mineral density in white and black women: evidence for racial differences in premenopausal bone homeostasis. J Clin Endocrinol Metab. 1989;69:762-770.
22. Jordan KM, Cooper C. Epidemiology of osteoporosis. Best Pract Res Clin Rheumatol. 202;16:795-806.
23. Looker AC, Wahner HW, Dunn WL, et al. Proximal femur bone mineral levels of U.S. adults. Osteoporos Int. 1995;5:389-400.
24. Seeman E. Periosteal bone formation - a neglected determinant of bone strength. N Engl J Med. 2003;349:320-323.
25. Fox KM, Cummings SR, Powell-Threets K, Stone K. Family history and risk of osteoporotic fracture. The Study of Osteoporotic Fractures Research Group. Osteoporos Int. 1998;8:557-562.
26. Rubin LA, Hawker GA, Peltekova VDE, et al. Determinants of peak bone mass: clinical and genetic analyses in a young female Canadian cohort. J Bone Miner Res. 1999;14:633-643.
27. Howard GM, Nguyen TV, Harris M, et al. Genetic and environmental contributions to the association between quantitative ultrasound and bone mineral density measurements: a twin study. J Bone Miner Res. 1998;13:1318-1327.
28. Slemenda CW, Christian JC, Williams CJ, et al. Genetic determinants of bone mass in adult women: a reevaluation of the twin model and the potential importance of gene interaction on heritability estimates. J Bone Miner Res. 1991;6:561-567.
29. Arden NK, Baker J, Hogg C, et al. The heritability of bone mineral density, ultrasound of the calcaneus and hip axis length: a study of postmenopausal twins. J Bone Miner Res. 1996;11:530-534.
30. Econs MJ, Speer MC. Genetic studies of complex diseases: let the reader beware. J Bone Miner Res. 1996;11:1835-1840.
31. Eisman JA. Genetics of osteoporosis. Endocr Rev. 1999;20:788-804.
32. Styrkarsdottir U, Cazier JB, Kong A, et al. Linkage of osteoporosis to chromosome 20p12 and association BMP2. PLoS Biol. 2003;1:351-360.
33. Johnson ML, Gong G, Kimberling W, et al. Linkage of a gene causing high bone mass to human chromosome 11 (11q12-13). Am J Hum Genet. 1997;60:1326-1332.
34. Little RD, Recker RR, Johnson ML. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002;347:943-944.
35. Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002;346:1513-1521.
36. Rissell-Aulet M, Shapiro B, Jaffe CA, et al. Peak bone mass in young healthy men is correlated with the magnitude of endogenous growth hormone secretion. J Clin Endcrincol Metab. 1998;83:3463-3468.
37. Halioua L, Anderson JJB. Lifetime calcium intake and physical activity habits: independent and combined effects on the radial bone of healthy premenopausal Caucasian women. Am J Clin Nutr. 1989;49:534-541.
38. Sandler RB, Slemenda C, LaPorte RE, et al. Postmenopausal bone density and milk consumption in childhood and adolescence. Am J Clin Nutr. 1985;42:270-274.
39. Soroko S, Holbrook TL, Edelstein S, Barrett-Connor E. Lifetime milk consumption and bone mineral density in older women. Am J Public Health. 1994;84:1319-1322.
40. Welten DC, Kemper HCG, Post GB, Van Staveren WA. A meta-analysis of the effect of calcium intake on bone mass in young and middle aged females and males. J Nutr. 1995;125:2802-2813.
41. Matkovic V, Kostial K, Simonovic I, et al. Bone status and fracture rates in two regions of Yugoslavia. Am J Clin Nutr. 1979;32:540-549.
42. Dietary Reference Intakes. Washington, DC: Food and Nutrition Board, Institute of Medicine, National Academy Press; 1997.
43. Heinonen A, Oja P, Kannus P, et al. Bone mineral density in female athletes representing sports with different loading characteristics of the skeleton. Bone. 1995;17:197-203.
44. Baxter-Jones AD, Mirwald RL, McKay HA, Bailey DA. A longitudinal analysis of sex differences in bone mineral accrual in healthy 8-19 year-old boys and girls. Ann Hum Biol. 2003;30:160-175.
45. Kannus P, Haapasalo H, Sankelo M, et al. Effect of starting age of physical activity on bone mass in the dominant arm of tennis and squash players. Ann Intern Med. 1995;123:27-31.
46. Welten DC, Kemper HCG, Post GB, et al. Weight-bearing activity during youth is a more important factor for peak bone mass than calcium intake. J Bone Miner Res. 1994;9:1089-1096.
47. Slemenda CW, Miller JZ, Hui SL, et al. Role of physical activity in the development of skeletal mass in children. J Bone Miner Res. 1991;6:1227-1233.
48. Wallace BA, Cumming RG. Systematic review of randomized trials of the effect of exercise on bone mass in pre- and postmenopausal women. Calcif Tissue Int. 2000;67:10-18.
49. Morris FL, Naughton GA, Gibbs JL, et al. Prospective ten-month exercise intervention in premenarcheal girls: positive effects on bone and lean mass. J Bone Miner Res. 1997;12:1453-1462.
50. Bradney M, Pearce G, Naughton G, et al. Moderate exercise during growth in prepubertal boys: changes in bone mass, size, volumetric density, and bone strength: a controlled prospective study. J Bone Miner Res. 1998;13:1814-1821.
51. Robinson RL, Snow-Harter C, Taaffe DR, et al. Gymnasts exhibit higher bone mass than runners despite similar prevalence of amenorrhea. J Bone Miner Res. 1995;10:26-35.
52. Jaffe DR, Snow-Harter C, Connolly DA, et al. Differential effects of swimming versus weight-bearing activity on bone mineral status of eumenorrheic athletes. J Bone Miner Res. 1995;10:586-593.
53. MacKelvie JK, Khan KM, Petit MA, Janssen PA, et al. A school-based exercise intervention elicits substantial bone health benefits: a 2-year randomized controlled trial in girls. Pediatrics. 2003;112:447-452.
54. Lindberg JS, Fears WB, Hunt MM. Exercise induced amenorrhea and bone density. Ann Intern Med. 1984;101:647-649.
55. Meyerson M, Gutin B, Warren MP, et al. Total body bone density in amenorrheic runners. Obstet Gynecol. 1992;79:973-978.
56. Fruth SJ, Worrell TW. Factors associated with menstrual irregularities and decreased bone mineral density in female athletes. J Orthop Sports Phys Ther. 1995;22:26-38.
57. Marcus R, Cann C, Madvig D. Menstrual function and bone mass in elite women distance runners. Ann Intern Med. 1985;102:158-163.
58. Myburgh KH, Bachrach LK, Lewis B, et al. Low bone mineral density at axial and appendicular sites in amenorrheic athletes. Med Sci Sports Exerc. 1993;25:1197-1202.
59. Davies KM, Peaerson PH, Huseman CA, et al. Reduced bone mineral in patients with eating disorders. Bone. 1990;11:143-147.
60. Bachrach LK, Katzman DK, Litt IF, Marcus R. Decreased bone density in adolescent girls with anorexia nervosa. Pediatrics. 1990;86:440-447.
61. Klibanski A, Neer RM, Beitins IZ, et al. Decreased bone density in hyperprolactinemic women. N Engl J Med. 1980;303:1511-1514.
62. Koppelman MCS, Kurtz DW, Morrish KA, et al. Vertebral body bone mineral content in hyperprolactinemic women. J Clin Endocrinol Metab. 1984;59:1050-1053.
63. Drinkwater BL, Nilson K, Ott S, Chesnut CH III. Bone mineral density after resumption of menses in amenorrheic women. JAMA. 1986;256:380-382.
64. Lindberg JS, Powell MR, Hunt MM, et al. Increased vertebral bone mineral in response to reduced exercise in amenorrheic women. West J Med. 1987;146:39-42.
65. Rencken ML, Chesnut CH III, Drinkwater BL. Bone density at multiple skeletal sites in amenorrheic athletes. JAMA. 1996;276:238-240.
66. Kaunitz AM. Injectable depot medroxyprogesterone acetate contraception: an update for clinicians. Int J Fertil Womens Med. 1998;43:73-83.
67. Cole RE. Normal bone remodeling process. Osteoporosis: Unmasking a Silent Thief. Brooklyn, Mich: Wellpower Publications; 2000.
68. Mundy GR, Boyce BF, Yoneda T, et al. Cytokines and bone remodeling. Osteoporosis. San Diego, Calif: Academic Press; 1996:477-482.
69. Horowitz MC. Cytokines and estrogens in bone: anti-osteoporotic effects. Science.1993;260:626-627.
70. Girasole G, Jilka RL, Passeri G, et al. 17-Beta-estradiol inhibits interleukin-6 production by bone marrow derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest. 1992;89:883-891.
71. Cheleuitte D, Mizuno S, Glowacki J. In vitro secretion of cytokines by human bone marrow: effects of age and estrogen status. J Clin Endocrinol Metab. 1998;83:2043-2051.
72. Cohen-Solal ME, Boitte F, Bernard-Poenaru O, et al. Increased bone resorbing activity of peripheral monocyte culture supernatants in elderly women. J Clin Endocrinol Metab. 1998;83:1687-1690.
73. Raisz LG. Local and systemic factors in the pathogenesis of osteoporosis. World Rev Nutr Diet. 1993;72:92-101.
74. Pacifici R, Brown C, Puscheck E, et al. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci U S A. 1991;88:5134-5138.
75. Jilka RL, Hangoe G, Girasole G. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science. 1992;257:88-91.
76. Burgess TL, Quian Y, Kaufman S, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol. 1999;145:527-538.
77. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A. 1998;95:3597-3602.
78. Arlot ME, Sornay-Rendu E, Garnero P, et al. Apparent pre- and postmenopausal loss evaluated by DXA at different skeletal sites in women: the OFELY cohort. J Bone Miner Res. 1997;12:683-690.
79. Steiniche T, Hasling C, Charles P, et al. A randomized study on the effects of estrogen/gestagen or high dose oral calcium on trabecular bone remodeling in postmenopausal osteoporosis. Bone. 1989;10:313-321.
80. Parfitt AM, Han ZH, Palnitkar S, et al. Effects of ethnicity and age or menopause on osteoblast function, bone mineralization, and osteoid accumulation in iliac bone. J Bone Miner Res. 1997;12:1864-1873.
81. Komm BS, Terpening CM, Benz DJ, et al. Estrogen binding receptor MRNA and biological response in osteoblast-like osteosarcoma cells. Science. 1988;241:81-84.
82. Onoe Y, Miyaura C, Ohta H, et al. Expression of estrogen receptor in rat bone. Endocrinology. 1997;138:4509-4512.
83. Arts J, Kuiper GGJM, Janssen JMMF, et al. Differential expression of estrogen receptors and mRNA during differentiation of human osteoblast SV-HFO cell. Endocrinology. 1997;138:5067-5070.
84. Shevde NK, Bendixen AC, Dienger KM, Pike JW. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci U S A. 2000;97:7829-7834.
85. Srivastava S, Toraldo G, Weitzmann MN, et al. Estrogen decreases osteoclast formation by down regulating RANKL induced JNK activation. J Biol Chem. 2001;276:8836-8840.
86. Johnston CC, Hui SL, Witt RM, et al. Early menopausal changes in bone mass and sex steroids. J Clin Endocrinol Metab. 1984;61:905-911.
87. Genant HK, Cann CE, Ettinger B, Gordan GS. Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy. Ann Intern Med. 1982;97:699-705.
88. Tremollieres FA, Pouilles JM, Ribot C. Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women. Osteoporos Int. 2001;12:385-390.
89. Riis BJ, Christiansen C. Measurement of spinal or peripheral bone mass to estimate early postmenopausal bone loss. Am J Med. 1988;84:646-653.
90. Calvo MS, Eyre DR, Gundberg CM. Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev. 1996;17:333-368.
91. Looker AC, Bauer DC, Chesnut CH III, et al. Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int. 2000;11:467-480.
92. Heaney RP. Calcium, parathyroid function, bone and aging. J Clin Endocrinol Metab. 1996;81:1697-1698.
93. Melton LJ III, Wahner HW, Richelson LS, et al. Osteoporosis and the risk for hip fracture. Am J Epidemiol. 1986;124:254-261.
94. Hui SL, Zhou L, Evans R, et al. Rates of growth and loss of bone mineral in the spine and femoral neck in white females. Osteoporos Int. 1999;9:200-205.
95. Looker AC, Wahner HW, Dunn WL, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int. 1998;8:468-489.
96. Ettinger B, Pressman A, Sklarin P, et al. Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the Study of Osteoporotic Fractures. J Clin Endocrinol Metab. 1998;83:2239-2243.
97. Greendale GA, Edelstein S, Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men. The Rancho Bernardo Study. J Bone Miner Res. 1997;12:1833-1843.
98. Khosla S, Bilezikian JP. The role of estrogens in men and androgens in women. Endocrinol Metab Clin North Am. 2003;32:195-218.
99. Slemenda CW, Longcope C, Zhou L, et al. Sex steroids and bone mass in older men: positive associations with serum estrogens and negative associations with androgens. J Clin Invest. 1997;100:1755-1759.
100. Heaney RP. Vitamin D, nutritional deficiency, and the medical paradigm. J Clin Endocrinol Metab. 2003;88:5107-5108.
101. Webb AR, Pilbeam C, Hanafin N, Holick MF. An evaluation of the relative contributions of exposure to sunlight and of diet to the circulating concentrations of 25-hydroxyvitamin D in an elderly nursing home population in Boston. Am J Clin Nutr. 1990;51:1075-1081.
102. Salamone LM, Dallal GE, Zantos D, et al. Contributions of vitamin D intake and seasonal sunlight exposure to plasma 25-hydroxyvitamin D concentration in elderly women. Am J Clin Nutr. 1993;58:80-86.
103. Prince RL, Dick IM, Devine A, et al. The effects of menopause and age on calcitropic hormones: a cross sectional study of 655 healthy women aged 35 to 90. J Bone Miner Res. 1995;10:835-842.
104. Eastell R, Yergey AL, Vieira NE, et al. Interrelation-ship among vitamin-D metabolism, true calcium-absorption, parathyroid function, and age in women: evidence of an age-related intestinal resistance to 1,25-dihydroxyvitamin-D action. J Bone Miner Res. 1991;6:125-132.
105. Ensrud KE, Duong T, Cauley JA, et al. Low fractional calcium absorption increases the risk for hip fracture in women with low calcium intake. Ann Intern Med. 2000;132:345-353.
106. Heany RP. Calcium, dairy products and osteoporosis. J Am Coll Nutr. 2000;19(suppl):83S-99S.
107. Nordin BEC, Need AG, Morris HA, Horowitz M. The nature and significance of the relation between urine sodium and urine calcium in women. J Nutr. 1993;123:1615-1622.
108. Linkswiler HM, Zemel MB, Hegsted M, Schuette S. Protein-induced hypercalciuria. Fed Proc. 1981;40:2429-2433.
109. Munger RG, Cerhan JR, Chiu BC. Prospective study of dietary protein intake and risk of hip fracture in postmenopausal women. Am J Clin Nutr. 1999;69:147-152.
110. Nordin BE. Calcium and osteoporosis. Review article. Nutrition. 1997;13:664-686.
111. Storm D, Eslin R, Porter ES, et al. Calcium supplementation prevents seasonal bone loss and changes in biochemical markers of bone turnover in elderly New England women. A randomized placebo-controlled trial. J Clin Endocrinol Metab. 1998;83:3817-3825.
112. Baeksgaard L, Andersen KP, Hyldstrup L. Calcium and vitamin D supplementation increases spinal BMD in healthy postmenopausal women. Osteoporos Int. 1998;8:255-260.
113. Reid IR, Ames RW, Evans MC, et al. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med. 1995;98:331-335.
114. Chevalley T, Rizzoli R, Nydegger V, et al. Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin-D-replete elderly patients. Osteoporos Int. 1994;4:245-252.
115. Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin d supplementation on bone density in men and women 65 years of age and older. N Engl J Med. 1997;337:670-676.
116. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med. 1992;327:1637-1642.
117. Munger RG, Cerhan JR, Chiu BC. Prospective study of dietary protein intake and risk of hip fracture in postmenopausal women. Am J Clin Nutr. 1999;69:147-152.
118. Johnell O, Gullberg B, Kanis JA, et al. Risk factors for hip fracture in European women: the MEDOS Study. Mediterranean Osteoporosis Study. J Bone Miner Res. 1995;10:1802-1815.
119. Huang Z, Himes JH, McGovern PG. Nutrition and subsequent hip fracture risk among a national cohort of white women. Am J Epidemiol. 1996;144:124-134.
120. Bonjour JP, Schurch MA, Rizzoli R. Proteins and bone health: older adults. Pathol Biol. 1997;45:57-59.
121. Heaney RP. Phosphorus nutrition and the treatment of osteoporosis. Mayo Clin Proc. 2004;79:91-97.
122. Durlach J, Bac P, Durlach V, et al. Magnesium status and aging: an update. Magnes Res. 1998;11:25-42.
123. Rude RK, Olerich M. Magnesium deficiency: possible role in osteoporosis associated with gluten-sensitive enteropathy, Osteoporos Int. 1996;6:453-461.
124. Hall SL, Greendale GA. The relationship of dietary vitamin C intake to bone mineral density. Results from the PEPI study. Calcif Tissue Int. 1998;63:183-189.
125. Booth SL. Skeletal functions of vitamin K-dependent proteins: not just for clotting anymore. Nutr Rev. 1997;55:282-284.
126. Tamatani M, Morimoto S, Nakajima M, et al. Participation of decreased circulating levels of vitamin K in bone mineral loss of elderly men. J Bone Miner Res. 1995;10:S248.
127. Szulc P, Chapuy MC, Meuniere PJ, Delmas PD. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest. 1993;91:1769-1774.
128. Hodges SJ, Akesson K, Vergnaud P, et al. Depressed levels of circulating menaquinones in patients with osteoporotic fractures of the spine and femoral neck. Bone. 1991;12:387-389.
129. Booth SI, Tucker KI, Chen H, et al. Dietary vitamin K intakes are associated with hip fracture but not with bone mineral density in elderly men and women. Am J Clin Nutr. 2000;71:1201-1208.
130. Feskanich D, Weber P, Willett WC, et al. Vitamin K intake and hip fracture in women. A prospective study. Am J Clin Nutr. 1999;69:74-79.
131. Vergnaud P, Garnero P, Meunier PJ, et al. Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture I elderly women. The EIPDOS Study. J Clin Endocrinol Metab. 1997;82:719-724.
132. Melhus H, Michaelsson K, Kindmark A, et al. Excessive dietary intake of vitamin A is associated with reduced bone mineral density and increased risk for hip fracture. Ann Intern Med. 1998;129:770-778.
133. Sigurdsson G. Dietary vitamin A intake and risk for hip fracture. Ann Intern Med. 1998;129:770-778.
134. Fesskanich D, Singh V, Willett WC, Colditz GA. Vitamin A intake and hip fractures among postmenopausal women. JAMA. 2002;287:47-54.
135. McLean RR, Jacques PF, Selhub J, et al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med. 2004;350:2042-2049.
136. van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med. 2004;350:2033-2041.
137. Gonzales-Calvin JL, Garcia-Sanchez A, Bellot V, et al. Mineral metabolism, osteoblastic function and bone mass in chronic alcoholism. Alcohol Alcoholism. 1993;28:571-579.
138. Felson DT, Kiel DP, Anderson JJ, Kannel WB. Alcohol consumption and hip fractures. The Framingham Study. Am J Epidemiol. 1998;128:1102-1110.
139. Feskanich D, Korrick SA, Greenspan SL, et al. Moderate alcohol consumption and bone density among postmenopausal women. J Womens Health. 1999;8:65-73.
140. Felson DT, Zhang Y, Hannan MT, et al. Alcohol intake and bone mineral density in elderly men and women. The Framingham Study. Am J Epidemiol. 1995;142:485-492.
141. Holbrook TL, Barrett-Connor E. A prospective study of alcohol consumption and bone mineral density. BMJ. 1993;306:1506-1509.
142. May H, Murphy S, Khaw KT. Alcohol consumption and bone mineral density in older men. Gerontology. 1995;41:152-158.
143. Grainge MJ, Coupland CA, Cliffe SJ, et al. Cigarette smoking, alcohol and caffeine consumption, and bone mineral density in postmenopausal women. The Nottingham EPIC Study Group. Osteoporos Int. 1998;8:355-363.
144. Ganry O, Baudoin C, Fardellone P. Effect of alcohol intake on bone mineral density in elderly women: The EPIDOS Study. Am J Epidemiol. 2000;151:773-780.
145. Naves Diaz M, O'Neill TW, Silman AJ. The influence of alcohol consumption and the risk of vertebral deformity. European Vetebral Osteoporosis Study Group. Osteoporos Int. 1997;7:65-71.
146. Krall EA, Dawson-Hughes B. Smoking and bone loss among postmenopausal women. J Bone Miner Res. 1991;6:331-338.
147. Bainbridge KE, Sowers M, Lin X, Harlow SD. Risk factors for low bone mineral density and the 6-year rate of bone loss among premenopausal and perimenopausal women. Osteoporos Int. 2004;15:439-446.
148. Gregg EW, Pereira MA, Caspersen CJ. Physical activity, falls, and fractures among older adults: a review of the epidemiologic evidence. J Am Geriatr Soc. 2000;48:883-893.
149. Gregg WE, Cauley JA, Seeley DG, et al. Physical activity and osteoporotic fracture risk in older women. An Intern Med. 1998;129:81-88.
150. Jaglal SB, Kreiger N, Darlington G. Past and recent physical activity and risk of hip fracture. Am J Epidemiol. 1993;138:107-118.
151. Jaglal SB, Kreiger N, Darlington GA. Lifetime occupational physical activity and risk of hip fracture in women. Ann Epidemiol. 1995:5:321-324.
152. Schwartz AV, Kelsey JL, Sidney S, Grisso JA. Characteristics of falls and risk of hip fracture in elderly men. Osteoporos Int. 1998;8:240-246.
153. Norton R, Campbell AJ, Lee-Joe T, et al. Circumstances of falls resulting in hip fractures among older people. J Am Geriatr Soc. 1997;45:1108-1112.
154. Greenspan SL, Myers ER, Maitland LA, et al. Fall severity and bone mineral density as risk factors for hip fracture in ambulatory elderly. JAMA. 1994;271:128-133.
155. Hayes WC, Myers ER, Morris JN, et al. Impact near the hip dominates fracture risk in elderly nursing home residents who fall. Calcif Tissue Int. 1993;52:192-198.
156. Maki BE, Holliday PJ, Topper AK. A prospective study of postural balance and risk of falling in an ambulatory and independent elderly population. J Gerontol. 1994;49:M72-84.
157. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med. 1988;319:1701-1707.
158. Graafmans WC, Ooms ME, Hofsree HMA, et al. Falls in the elderly. A prospective study of risk factors and risk profiles. Am J Epidemiol. 1996;143:1129-1136.
159. Sorock GS, Labiner DM. Peripheral neuromuscular dysfunction and falls in an elderly cohort. Am J Epidemiol. 1992;136:584-591.
160. O'Loughlin JL, Robitaille Y, Boilvin J, Suissa S. Incidence of and risk factors for falls and injurious falls among the community-dwelling elderly. Am J Epidemiol. 1993;137:342-354.
161. Tinetti ME, Doucette J, Claus E, Marottoli R. Risk factors for serious injury furing falls by older persons in the community. J Am Geriatr Soc. 1995;43:1214-1221.
162. National Osteoporosis Foundation. Osteoporosis: review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis, status report. Osteoporos Int. 1998;(suppl4):S1-S88.
163. Adachi JD, Olsynski WP, Hanley DA, et al. Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum. 2000;29:228-251.
164. Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J Bone Miner Res. 1996;11:1531-1538.
165. Van Daele PLA, Seibel MJ, Burger H, et al. Case-control analysis of bone resorption markers, disability, and hip fracture risk: The Rotterdam Study. BMJ. 1996;312:482-483.
166. Akesson K, Ljunghall S, Jonsson B, et al. Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture: a retrospective and prospective population-based study of women. J Bone Miner Res. 1995;10:1823-1829.
167. Watts NB, Harris ST, Genant HK. Treatment of painful osteoporotic vertebral fractures with percutaneous vertebroplasty or kyphoplasty. Osteoporos Int. 2001;12:429-437.
168. Donovan MA, Khandji AG, Siris E. Multiple adjacent vertebral fractures after kyphoplasty in a patient with steroid-induced osteoporosis. J Bone Miner Res. 2004;19:712-714.
169. Lindsay R, Cosman F. Estrogen-dependent bone loss and osteoporosis. In: Orwoll E, ed. Atlas of Osteoporosis. Philadelphia, Pa: Current Medicine, Inc.; 2003:95-104.
170. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Pregestin Interventions (PEPI) Trial. JAMA. 1996;275:1389-1396.
171. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA. 2002;287:2668-2676.
172. Lindsay R, Hart DM, Forrest C, Baird C. Prevention of spinal osteoporosis in oophorectomised women. Lancet. 1980;2:1151-1153.
173. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transderman estrogen. Ann Intern Med. 1992;117:1-9.
174. Rossouw JE, Anderson GL, Kooperber C, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
175. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative Randomized Controlled Trial. JAMA. 2004;291:1703-1712.
176. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer. Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-1388.
177. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA. 1999;282:637-645.
178. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002;87:3609-3617.
179. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Rest Treatment. 2001;65:124-134.
180. Cummings SR, Eckert S, Krueger KA, et al. The effects of raloxifene on risk of breast caner in postmenopausal women. Results from the MORE randomized trial. JAMA. 1999;281:2189-2197.
181. Nickelsen T, Lifkin EG, Riggs BL, et al. Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women. Psychoneuroendocrinology. 1999;24:115-128.
182. Yaffe K, Krueger K, Sarkar S, et al. Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med. 2001;344:1207-1213.
183. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year randomized trial. JAMA. 2002;287:847-857.
184. Liberman UA, Weiss SR, Broll J, et al. Effect of alendronate on BMD and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995;36:612-613.
185. Cranney A, Wells G, Willan A, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev. 2002;23:508-516.
186. Black D, Cummings S, Karpf D, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535-1541.
187. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA. 1998;280:2077-2082.
188. Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group. Osteoporos Int. 1999;9:461-468.
189. Bauer DC, Black D, Ensrud K, et al. Upper gastrointestinal tract safety profile of alendronate. The Fracture Intervention Trial. Arch Intern Med. 2000;160:517-525.
190. Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano). 2000;12:1-12.
191. Harris ST, Watts NB, Genant HK, et al. Effect of risedronate treatment on vertebral and non vertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA. 1999:282:1344-1352.
192. Cranney A, Tugwell P, Adachi J, et al. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev. 2002;23:517-523.
193. Harris ST, Watts NB, Genant HK, et al. Effect of risedronate treatment on vertebral and non vertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA. 1999;282:1344-1352.
194. Reginster JY, Minne H, Sorensen O, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 2000;11:83-91.
195. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344:333-340.
196. Silverman SL. Calcitonin. In: Osteoporosis: An Evidence-Based Guide To Prevention and Management. Philadelphia: Pa: American College of Physicians; 2002:197-208.
197. Chestnut CH III, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000;109:267-276.
198. Cosman R, Lindsay R. Therapeutic potential of parathyroid hormone. Curr Osteoporos Rep. 2004;2:5-11.
199. Dempster DW, Cosman F, Kurland ES, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res. 2001;16:1846-1853.
200. Cosman F, Nieves J, Woelfert L, et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after PTH withdrawal. J Bone Miner Res. 2001;16:925-931.
201. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in post-menopausal women with osteoporosis. N Engl J Med. 2001;344:1434-1441.
202. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349:1207-1215.
203. Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003:349:1216-1226.
204. Ettinger B, San Martin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res. 2004;19:745-751.
205. Ma YL, Bryant HU, Zeng Q, et al. New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats. Endocrinology. 2003;144:2008-2015.
206. Lauritzen JB, Petersen MM, Lund B. Effect of external hip protectors on hip fractures. Lancet. 1993;341:11-13.
207. Ekman A, Mallmin H, Michaelsson K, Ljunghall S. External hip protectors to prevent osteoporotic hip fractures. Lancet. 1997;350:563-564.
208. Kannus P, Parkkari J, Niemi S, et al. Prevention of hip fracture in elderly people with use of a hip protector. N Engl J Med. 2000;343:1506-1513.
209. Cummings SR, Palermo L, Browner W, et al. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA. 2000;283:1318-1321.